A chymotryptic-type serine protease is required for IL-2 production by Jurkat T cells.
Interleukin-2 (IL-2) production by activated Jurkat T cells was markedly delayed when these cells were treated with low concentrations of the chymotryptic-type protease inhibitor N-alpha-p-tosyl-L-phenylalanine chloromethylketone (TPCK). This increased lag time observed in the presence of TPCK directly correlates with the interaction of the inhibitor with a unique 42,000 molecular weight (MW) serine protease, which can be labelled with [3H]DFP, and was not due to an intracellular accumulation of a non-mature form of IL-2 nor to a non-specific inhibition of overall protein synthesis. The results presented in this report indicate that a 42,000 MW chymotryptic-like serine protease is required for IL-2 production by activated Jurkat T cells.
Auberger
P
P
INSERM U210, Faculte de Medecine, Nice, France.
Sonthonnax
S
S
Peyron
J F
JF
Mari
B
B
Fehlmann
M
M
D002460:Cell Line; D002918:Chymotrypsin / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D007376:Interleukin-2 / Q000096:biosynthesis*; D007700:Kinetics; D013601:T-Lymphocytes / Q000276:immunology*; D014108:Tosylphenylalanyl Chloromethyl Ketone / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000276:immunology
D007376:Interleukin-2; D014108:Tosylphenylalanyl Chloromethyl Ketone; D002918:Chymotrypsin